16 results on '"Position paper"'
Search Results
2. Oral corticosteroids stewardship for asthma in adults and adolescents: A position paper from the Thoracic Society of Australia and New Zealand.
- Author
-
Blakey, John, Chung, Li Ping, McDonald, Vanessa M., Ruane, Laurence, Gornall, John, Barton, Chris, Bosnic‐Anticevich, Sinthia, Harrington, John, Hew, Mark, Holland, Anne E., Hopkins, Trudy, Jayaram, Lata, Reddel, Helen, Upham, John W., Gibson, Peter G., and Bardin, Philip
- Subjects
- *
ASTHMA , *ADULTS , *TEENAGERS , *CORTICOSTEROIDS , *PATIENTS' attitudes - Abstract
Oral corticosteroids (OCS) are frequently used for asthma treatment. This medication is highly effective for both acute and chronic diseases, but evidence indicates that indiscriminate OCS use is common, posing a risk of serious side effects and irreversible harm. There is now an urgent need to introduce OCS stewardship approaches, akin to successful initiatives that optimized appropriate antibiotic usage. The aim of this TSANZ (Thoracic Society of Australia and New Zealand) position paper is to review current knowledge pertaining to OCS use in asthma and then delineate principles of OCS stewardship. Recent evidence indicates overuse and over‐reliance on OCS for asthma and that doses >1000 mg prednisolone‐equivalent cumulatively are likely to have serious side effects and adverse outcomes. Patient perspectives emphasize the detrimental impacts of OCS‐related side effects such as weight gain, insomnia, mood disturbances and skin changes. Improvements in asthma control and prevention of exacerbations can be achieved by improved inhaler technique, adherence to therapy, asthma education, smoking cessation, multidisciplinary review, optimized medications and other strategies. Recently, add‐on therapies including novel biological agents and macrolide antibiotics have demonstrated reductions in OCS requirements. Harm reduction may also be achieved through identification and mitigation of predictable adverse effects. OCS stewardship should entail greater awareness of appropriate indications for OCS prescription, risk–benefits of OCS medications, side effects, effective add‐on therapies and multidisciplinary review. If implemented, OCS stewardship can ensure that clinicians and patients with asthma are aware that OCS should not be used lightly, while providing reassurance that asthma can be controlled in most people without frequent use of OCS. See relatedEditorial [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. Positionspapier „Beton ohne Steinkohlenflugasche": Veränderung der Betonbauweise aufgrund abnehmender Verfügbarkeit von Steinkohlenflugasche und anderen Kraftwerksnebenprodukten als Zusatzstoffe für Beton.
- Author
-
Voland, Katja and Westendarp, Andreas
- Subjects
- *
ANTHRACITE coal , *COAL ash , *FLY ash , *CONCRETE , *CONCRETE construction - Abstract
Position paper "Concrete without hard coal fly ash" – Change in concrete construction due to decreasing availability of hard coal fly ash and other power plant by‐products as additives for concrete Due to the gradual phase‐out of coal‐fired power generation, significantly lower volumes of hard coal fly ash produced in Germany are already available today. By 2038 at the latest, their share will fall to zero. The German Society for Concrete and Construction Technology (DBV) and the Federal Waterways Engineering and Research Institute (BAW) are pursuing the aim of this position paper to inform all those involved in construction about the resulting supply bottlenecks of hard coal fly ash and to create understanding. In addition, in this paper they show initial approaches to solutions to minimize the negative effects on concrete construction as far as possible. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. COVID‐19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper.
- Author
-
Pfaar, Oliver, Klimek, Ludger, Jutel, Marek, Akdis, Cezmi A., Bousquet, Jean, Breiteneder, Heimo, Chinthrajah, Sharon, Diamant, Zuzana, Eiwegger, Thomas, Fokkens, Wytske J., Fritsch, Hans‐Walter, Nadeau, Kari C., O'Hehir, Robyn E., O'Mahony, Liam, Rief, Winfried, Sampath, Vanitha, Schedlowski, Manfred, Torres, María José, Traidl‐Hoffmann, Claudia, and Wang, De Yun
- Subjects
- *
COVID-19 pandemic , *COVID-19 , *MEDICAL personnel , *SARS-CoV-2 - Abstract
Background: The coronavirus disease 2019 (COVID‐19) has evolved into a pandemic infectious disease transmitted by the severe acute respiratory syndrome coronavirus (SARS‐CoV‐2). Allergists and other healthcare providers (HCPs) in the field of allergies and associated airway diseases are on the front line, taking care of patients potentially infected with SARS‐CoV‐2. Hence, strategies and practices to minimize risks of infection for both HCPs and treated patients have to be developed and followed by allergy clinics. Method: The scientific information on COVID‐19 was analysed by a literature search in MEDLINE, PubMed, the National and International Guidelines from the European Academy of Allergy and Clinical Immunology (EAACI), the Cochrane Library, and the internet. Results: Based on the diagnostic and treatment standards developed by EAACI, on international information regarding COVID‐19, on guidelines of the World Health Organization (WHO) and other international organizations, and on previous experience, a panel of experts including clinicians, psychologists, IT experts, and basic scientists along with EAACI and the "Allergic Rhinitis and its Impact on Asthma (ARIA)" initiative have developed recommendations for the optimal management of allergy clinics during the current COVID‐19 pandemic. These recommendations are grouped into nine sections on different relevant aspects for the care of patients with allergies. Conclusions: This international Position Paper provides recommendations on operational plans and procedures to maintain high standards in the daily clinical care of allergic patients while ensuring the necessary safety measures in the current COVID‐19 pandemic. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Placebo effects in allergen immunotherapy—An EAACI Task Force Position Paper.
- Author
-
Pfaar, Oliver, Agache, Ioana, Bergmann, Karl‐Christian, Bindslev‐Jensen, Carsten, Bousquet, Jean, Creticos, Peter S., Devillier, Philippe, Durham, Stephen R., Hellings, Peter, Kaul, Susanne, Kleine‐Tebbe, Jörg, Klimek, Ludger, Jacobsen, Lars, Jutel, Marek, Muraro, Antonella, Papadopoulos, Nikolaos G., Rief, Winfried, Scadding, Glenis K., Schedlowski, Manfred, and Shamji, Mohamed H.
- Subjects
- *
PLACEBOS , *TASK forces , *ALLERGENS , *CLINICAL trials , *IMMUNOTHERAPY - Abstract
The placebo (Latin "I will please") effect commonly occurs in clinical trials. The psychological and physiological factors associated with patients' expectations about a treatment's positive and negative effects have yet to be well characterized, although a functional prefrontal cortex and intense bidirectional communication between the central nervous system and the immune system appear to be prerequisites for a placebo effect. The use of placebo raises certain ethical issues, especially if patients in a placebo group are denied an effective treatment for a long period of time. The placebo effect appears to be relatively large (up to 77%, relative to pretreatment scores) in controlled clinical trials of allergen immunotherapy (AIT), such as the pivotal, double‐blind, placebo‐controlled (DBPC) randomized clinical trials currently required by regulatory authorities worldwide. The European Academy of Allergy and Clinical Immunology (EAACI) therefore initiated a Task Force, in order to better understand the placebo effect in AIT and its specific role in comorbidities, blinding issues, adherence, measurement time points, variability and the natural course of the disease. In this Position Paper, the EAACI Task Force highlights several important topics regarding the placebo effect in AIT such as a) regulatory aspects, b) neuroimmunological and psychological mechanisms, c) placebo effect sizes in AIT trials, d) methodological limitations in AIT trial design and e) potential solutions in future AIT trial design. In conclusion, this Position Paper aims to examine the methodological problem of placebo in AIT from different aspects and also to highlight unmet needs and possible solutions for future trials. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Management of burning mouth Syndrome: A position paper of the Chinese Society of Oral Medicine.
- Author
-
Chen, Qianming, Shi, Yujie, Jiang, Lu, Zhou, Yu, Dan, Hongxia, Jin, Xin, Sun, Silu, and Zeng, Xin
- Subjects
- *
BURNING mouth syndrome treatment , *ORAL medicine , *PAIN management , *PHYSICAL therapy - Abstract
Background: Burning mouth syndrome is a syndrome with tongue as the main affected site and burning pain as the main complaint. Although a variety of therapies have been reported to treat BMS, there is a lack of widely recognized therapies and it is still a dilemma for clinicians to treat BMS.Objective: To develop the position paper and provide the references for clinical practice of BMS in China.Methods: Under the guidance of WHO (World Health Organization) Handbook for Guideline Development, we used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach as a tool to develop this position paper in the following steps: setting up the groups, formulating the clinical questions and choosing the outcomes, retrieving and synthesizing of evidence, assessing the evidence, investigating the patients' values and preferences, developing the recommendations, reviewing the recommendations, and writing the position paper.Results: The 27 recommendations were formed from the following 7 aspects: pre-treatment examination, removal of stimuli, medication, physical therapy, psychological therapy, and antipsychotics. There are 3 strong recommendations and 12 weak recommendations in pre-treatment examination and removal of stimuli, as well as 12 weak recommendations in therapies.Conclusion: The Chinese position paper for management of BMS has been developed, which could provide the references for clinical practice of BMS in China. Twenty-seven recommendations were formed based on consensus of experts on the balance of benefits vs side effects, evidence, cost, and patients' values and preferences, although the quality of evidence is relatively low. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
7. French neonatal society position paper stresses the importance of an early family-centred approach to discharging preterm infants from hospital.
- Author
-
Pladys, Patrick, Zaoui, Catherine, Girard, Laurence, Mons, Fabienne, Reynaud, Audrey, Casper, Charlotte, Kuhn, P, Souet, G, Fichtner, C, Laprugne‐garcia, E, Legouais, S, Zores, C, Thiriez, G, Duboz, M A, Knezovic‐Daniel, N, Renesme, L, Brandicourt, A, Gonnaud, F, Picaud, JC, and Julie‐Fische, C
- Subjects
- *
PREMATURE infants , *NEWBORN infants , *MEDICAL personnel , *POST-traumatic stress , *MEDICAL supplies , *HOSPITALS , *NEONATAL intensive care , *NEONATAL intensive care units , *DISCHARGE planning , *PARENTS - Abstract
Aim: The families of hospitalised preterm infants risk depression and post-traumatic stress and the preterm infants risk re-hospitalisation. The French neonatal society's aim was to review the literature on how the transition from hospital to home could limit these risks and to produce a position paper.Methods: A systematic literature review was performed covering 1 January 2000 to 1 January 2018, and multidisciplinary experts examined the scientific evidence.Results: We identified 939 English and French papers and 169 are quoted in the position paper. Most studies stressed the importance of early, personalised and progressive involvement of the family. Healthcare staff and families should assess discharge preparations jointly. This evaluation should assess the capacities of the newborn infant, with regard to its physiological maturity. It should also assess the family's ability to supply the medical, psychological and social assistance required before and after discharge. There should be a structured follow-up process that includes effective communication, various tools, interventions, networks, health and social professionals.Conclusion: Discharge preparations may improve the transition from hospital to home and the outcomes for the parents and newborn preterm infant. This early family-centred approach should be structured, coordinated and based on individual needs and circumstances. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
8. The role of mobile health technologies in allergy care: An EAACI position paper.
- Author
-
Matricardi, Paolo Maria, Dramburg, Stephanie, Alvarez‐Perea, Alberto, Antolín‐Amérigo, Darío, Apfelbacher, Christian, Atanaskovic‐Markovic, Marina, Berger, Uwe, Blaiss, Michael S., Blank, Simon, Boni, Elisa, Bonini, Matteo, Bousquet, Jean, Brockow, Knut, Buters, Jeroen, Cardona, Victoria, Caubet, Jean‐Christoph, Cavkaytar, Özlem, Elliott, Tania, Esteban‐Gorgojo, Ignacio, and Fonseca, Joao A.
- Subjects
- *
MEDICAL technology , *MEDICAL personnel , *FOOD allergy , *MEDICAL care accountability , *DRUG allergy , *ALLERGIC rhinitis - Abstract
Mobile health (mHealth) uses mobile communication devices such as smartphones and tablet computers to support and improve health‐related services, data and information flow, patient self‐management, surveillance, and disease management from the moment of first diagnosis to an optimized treatment. The European Academy of Allergy and Clinical Immunology created a task force to assess the state of the art and future potential of mHealth in allergology. The task force endorsed the "Be He@lthy, Be Mobile" WHO initiative and debated the quality, usability, efficiency, advantages, limitations, and risks of mobile solutions for allergic diseases. The results are summarized in this position paper, analyzing also the regulatory background with regard to the "General Data Protection Regulation" and Medical Directives of the European Community. The task force assessed the design, user engagement, content, potential of inducing behavioral change, credibility/accountability, and privacy policies of mHealth products. The perspectives of healthcare professionals and allergic patients are discussed, underlining the need of thorough investigation for an effective design of mHealth technologies as auxiliary tools to improve quality of care. Within the context of precision medicine, these could facilitate the change in perspective from clinician‐ to patient‐centered care. The current and future potential of mHealth is then examined for specific areas of allergology, including allergic rhinitis, aerobiology, allergen immunotherapy, asthma, dermatological diseases, food allergies, anaphylaxis, insect venom, and drug allergy. The impact of mobile technologies and associated big data sets are outlined. Facts and recommendations for future mHealth initiatives within EAACI are listed. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. Biological membranes in EV biogenesis, stability, uptake, and cargo transfer: an ISEV position paper arising from the ISEV membranes and EVs workshop.
- Author
-
Russell, Ashley E., Sneider, Alexandra, Witwer, Kenneth W., Bergese, Paolo, Bhattacharyya, Suvendra N., Cocks, Alexander, Cocucci, Emanuele, Erdbrügger, Uta, Falcon-Perez, Juan M., Freeman, David W., Gallagher, Thomas M., Hu, Shuaishuai, Huang, Yiyao, Jay, Steven M., Kano, Shin-ichi, Lavieu, Gregory, Leszczynska, Aleksandra, Llorente, Alicia M., Lu, Quan, and Mahairaki, Vasiliki
- Abstract
Paracrine and endocrine roles have increasingly been ascribed to extracellular vesicles (EVs) generated by multicellular organisms. Central to the biogenesis, content, and function of EVs are their delimiting lipid bilayer membranes. To evaluate research progress on membranes and EVs, the International Society for Extracellular Vesicles (ISEV) conducted a workshop in March 2018 in Baltimore, Maryland, USA, bringing together key opinion leaders and hands-on researchers who were selected on the basis of submitted applications. The workshop was accompanied by two scientific surveys and covered four broad topics: EV biogenesis and release; EV uptake and fusion; technologies and strategies used to study EV membranes; and EV transfer and functional assays. In this ISEV position paper, we synthesize the results of the workshop and the related surveys to outline important outstanding questions about EV membranes and describe areas of consensus. The workshop discussions and survey responses reveal that while much progress has been made in the field, there are still several concepts that divide opinion. Good consensus exists in some areas, including particular aspects of EV biogenesis, uptake and downstream signalling. Areas with little to no consensus include EV storage and stability, as well as whether and how EVs fuse with target cells. Further research is needed in these key areas, as a better understanding of membrane biology will contribute substantially towards advancing the field of extracellular vesicles. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. EAACI/ENDA Position Paper: Diagnosis and management of hypersensitivity reactions to non‐steroidal anti‐inflammatory drugs (NSAIDs) in children and adolescents.
- Author
-
Kidon, Mona, Caubet, Jean Christoph, Soyer, Ozge, Mori, Francesca, Blanca, Miguel, Atanaskovic‐Markovic, Marina, Blanca‐Lopez, Natalia, Gomes, Eva, Terreehorst, Ingrid, Tanno, Luciana, Ponvert, Claude, and Chin, Chiang Wen
- Subjects
- *
ANTI-inflammatory agents , *ALLERGIES , *PHENOTYPES , *JUVENILE diseases , *INDOMETHACIN - Abstract
Abstract: Non‐steroidal anti‐inflammatory drugs (NSAIDs) are commonly used in the pediatric population as antipyretics/analgesics and anti‐inflammatory medications. Hypersensitivity (HS) reactions to NSAID in this age group, while similar to adults, have unique diagnostic and management issues. Although slowly accumulating, published data in this age group are still relatively rare and lacking a unifying consensus. This work is a summary of current knowledge and consensus recommendations utilizing both published data and expert opinion from the European Network of Drug Allergy (ENDA) and the Drug Hypersensitivity interest group in the European Academy of Allergy and Clinical Immunology (EAACI). This position paper summarizes diagnostic and management guidelines for children and adolescents with NSAIDs hypersensitivity. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
11. Position paper on diagnosis and treatment of atopic dermatitis.
- Author
-
Darsow, U., Lübbe, J., Taïeb, A., Seidenari, S., Wollenberg, A., Calza, A.M., Giusti, F., and Ring, J.
- Subjects
- *
ATOPIC dermatitis , *ALLERGIES , *SKIN inflammation , *ANTI-infective agents , *IMMUNOLOGICAL adjuvants , *FOOD allergy - Abstract
The diagnosis of atopic dermatitis (AD) is made using evaluated clinical criteria. Management of AD must consider the symptomatic variability of the disease. It is based on hydrating topical treatment, and avoidance of specific and unspecific provocation factors. Anti-inflammatory treatment is used for exacerbation management. Topical corticosteroids remain the first choice. Systemic anti-inflammatory treatment should be kept to a minimum, but may be necessary in rare refractory cases. The new topical calcineurin inhibitors (tacrolimus and pimecrolimus) expand the available choices of topical anti-inflammatory treatment. Microbial colonization and superinfection (e.g. withStaphylococcus aureus,Malassezia furfur) can have a role in disease exacerbation and can justify the use of antimicrobials in addition to the anti-inflammatory treatment. Evidence for the efficacy of systemic antihistamines in relieving pruritus is still insufficient, but some patients seem to benefit. Adjuvant therapy includes ultraviolet (UV) irradiation preferably of UVA wavelength; UVB 311 nm has also been used successfully. Dietary recommendations should be specific and only given in diagnosed individual food allergy. Stress-induced exacerbations may make psychosomatic counselling recommendable.‘Eczema school’ educational programmes have proved to be helpful. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
12. European task force on atopic dermatitis position paper
- Author
-
Regina Fölster-Holst, Thomas Werfel, Michael J. Cork, Alain Taieb, Julien Seneschal, Carle Paul, Åke Svensson, Carsten Flohr, Thomas Bieber, Phyllis I. Spuls, Sébastien Barbarot, Uwe Gieler, J. Ring, Christian Vestergaard, L.B. von Kobyletzki, Stéphanie Christen-Zaech, Jacob P. Thyssen, M S de Bruin-Weller, DirkJan Hijnen, Ulf Darsow, Andreas Wollenberg, J. F. Stalder, Magdalena Trzeciak, Carlo Gelmetti, Pavel V Chernyshov, Dagmar Simon, M. Deleuran, B. Kunz, L. De Raeve, Surgical clinical sciences, Dermatology, Skin function and permeability, APH - Methodology, APH - Quality of Care, Aarhus University Hospital, Ludwig Maximilians University of Munich, Hôpital Municipal de Munich, Partenaires INRAE, Centre hospitalier universitaire de Nantes (CHU Nantes), Lausanne University Hospital, University of Amsterdam [Amsterdam] (UvA), King‘s College London, Medical University of Gdańsk, Lund University [Lund], Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Larrey [Toulouse], CHU Toulouse [Toulouse], University of Bonn, Hannover Medical School [Hannover] (MHH), Department of Dermatology, Venerology and Allergology, Universitätsklinikum Würzburg, Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), Justus-Liebig-Universität Gießen (JLU), University of Sheffield, Vrije Universiteit Brussel (VUB), Dermatologikum Hamburg, Universität Bern- University of Bern [Bern], National Medical University Kief, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Università degli Studi di Milano [Milano] (UNIMI), Christine Kühne Center, University Medical Center [Utrecht], University of Copenhagen = Københavns Universitet (KU), ProdInra, Migration, Ludwig-Maximilians University [Munich] (LMU), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Justus-Liebig-Universität Gießen = Justus Liebig University (JLU), Università degli Studi di Milano = University of Milan (UNIMI), and University of Copenhagen = Københavns Universitet (UCPH)
- Subjects
0301 basic medicine ,Male ,Pediatrics ,Azathioprine ,disease flares ,Ultraviolet therapy ,Preconception Care ,030207 dermatology & venereal diseases ,0302 clinical medicine ,tacrolimus ointment ,Dermatitis, Atopic/therapy ,guidelines ,Dermatologic Agents/therapeutic use ,Atopic dermatitis ,calcineurin inhibitors ,3. Good health ,Europe ,Infectious Diseases ,Female ,Ultraviolet Therapy ,eczema ,pregnancy ,treatment options ,medicine.drug ,Adult ,medicine.medical_specialty ,Advisory Committees ,Dermatology ,Dermatitis, Atopic ,03 medical and health sciences ,[SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics ,children ,medicine ,Humans ,Lactation ,Pregnancy ,[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics ,business.industry ,Chlorhexidine ,birth outcomes ,[SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatology ,medicine.disease ,Tacrolimus ,[SDV.AEN] Life Sciences [q-bio]/Food and Nutrition ,030104 developmental biology ,antirheumatic drugs ,maternal stress ,Position paper ,Dermatologic Agents ,business ,[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition ,[SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology - Abstract
International audience; Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the treatment of pregnant or lactating women and for adults planning to have a child are often lacking. This position paper from the European Task force on Atopic Dermatitis (ETFAD) is based on up-to-date scientific literature on treating pregnant and lactating women as wells as adults with AD planning to have a child. It is based on the expert opinions of members of the ETFAD and on existing safety data on the proposed treatments, many of which are derived from patients with other inflammatory diseases or from transplantation medicine. For treating future parents, as well as pregnant and lactating women with AD, the use of topical treatments including moisturizers, topical corticosteroids, tacrolimus, antiseptics such as chlorhexidine, octenidine, potassium permanganate and sodium hypochlorite (bleach) is deemed to be safe. Ultraviolet (UV) therapy may also be used. Systemic treatment should be prescribed only after careful consideration. According to the opinion of the ETFAD, treatment should be restricted to systemic corticosteroids and cyclosporine A, and, in selected cases, azathioprine.
- Published
- 2019
13. A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis
- Author
-
J. D. Boot, R. van Ree, Dirk-Jan Opstelten, E van Twuijver, Oliver Pfaar, Zuzana Diamant, P. Panzner, Piotr Kuna, Ludger Klimek, AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, and Experimental Immunology
- Subjects
Male ,0301 basic medicine ,SYMPTOMS ,Phases of clinical research ,nasal provocation ,medicine.disease_cause ,Immunoglobulin E ,Gastroenterology ,DOUBLE-BLIND ,0302 clinical medicine ,Allergen ,Immunology and Allergy ,birch pollen ,Betula ,biology ,dose finding ,Middle Aged ,Slit ,Treatment Outcome ,Tolerability ,Pollen ,Female ,Original Article ,POSITION PAPER ,Adult ,Allergen immunotherapy ,medicine.medical_specialty ,Adolescent ,Airway Diseases ,Immunology ,DIAGNOSIS ,sublingual immunotherapy ,PARAMETERS ,Medication Adherence ,Young Adult ,03 medical and health sciences ,Internal medicine ,Immune Tolerance ,medicine ,Humans ,CLINICAL-EFFICACY ,Skin Tests ,Asthma ,Plant Extracts ,business.industry ,Rhinitis, Allergic, Seasonal ,Allergens ,medicine.disease ,RHINOCONJUNCTIVITIS ,030104 developmental biology ,030228 respiratory system ,Desensitization, Immunologic ,biology.protein ,allergen immunotherapy ,ASTHMA ,ORIGINAL ARTICLES ,business ,FOLLOW-UP - Abstract
Background: Sublingual immunotherapy (SLIT) is a potential efficacious and safe treatment option for patients with respiratory, IgE-mediated allergic diseases. A combined tolerability, dose-finding study with a sublingual liquid birch pollen preparation (SB) was conducted.Methods: Two hundred and sixty-nine adults with birch-pollen-induced AR were randomized to placebo, SB: 3333, 10 000, 20 000 or 40 000 AUN/ml. Differences in symptom scores following a titrated nasal provocation test (TNPT) at baseline and after 5 months of treatment were determined. Safety, tolerability, birch-pollen- specific immunoglobulin levels and peak nasal inspiratory flow (PNIF) were also measured (all measures determined outside the birch pollen season).Results: In all treatment groups, an improvement in symptom scores after treatment compared to baseline was observed, with an additional stepwise improvement in the active groups compared to placebo, which was significant in high-dose groups (P = 0.008 and P Conclusions: A multicentre trial evaluated the dose-response and tolerability of SB. All active treatment groups showed better responses than placebo for both primary and secondary parameters. The results indicate that, within the studied dose range, SB 40 000 AUN/ml is the most optimal effective and safe dose (ClinicalTrials.gov: NCT01639768).
- Published
- 2016
14. Postgraduate periodontal education: scope, competences, proficiencies and learning outcomes: Consensus report of the 1st European workshop on periodontal education - position paper 3 and consensus view 3
- Author
-
Mariano Sanz, U. van der Velden, OWI (ACTA), and Parodontologie (OUD, ACTA)
- Subjects
Medical education ,Certification ,Scope (project management) ,business.industry ,Periodontology ,Dental education ,Education, Dental, Graduate ,Competency-Based Education ,Education ,Europe ,Humans ,Periodontics ,Position paper ,Medicine ,Curriculum ,Educational Measurement ,business ,General Dentistry - Published
- 2010
15. Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper
- Author
-
Pm Mertes, S Nasser, Am Chiriac, María José Torres, Miguel Blanca, Pascal Demoly, E Castro, S. Testi, Knut Brockow, M. B. Bilò, J. Ring, Lh Garvey, Axel Trautmann, B Schnyder, Paolo Campi, Audrey Romano, A. Barbaud, Andreas J. Bircher, Holger Mosbech, Ingrid Terreehorst, Carla Lombardo, B Bonadonna, J Gooi, Martine Grosber, Kathrin Scherer, M. Pagani, Werner Aberer, Marina Atanaskovic-Markovic, Jr Cernadas, Surgical clinical sciences, Specialities, Skin function and permeability, Other Research, Paediatric Pulmonology, and Ear, Nose and Throat
- Subjects
Hypersensitivity, Immediate ,Drug ,medicine.medical_specialty ,Allergy ,diagnosis ,media_common.quotation_subject ,Immunology ,Drug allergy ,MEDLINE ,skin test ,Pharmacology ,Sensitivity and Specificity ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,intradermal test ,medicine ,Humans ,Immunology and Allergy ,Hypersensitivity, Delayed ,Intensive care medicine ,Skin Tests ,media_common ,business.industry ,Perioperative ,Skin test ,medicine.disease ,3. Good health ,Interest group ,Position paper ,business ,drug allergy ,drug hypersensitivity ,030215 immunology - Abstract
Skin tests are of paramount importance for the evaluation of drug hypersensitivity reactions. Drug skin tests are often not carried out because of lack of concise information on specific test concentrations. The diagnosis of drug allergy is often based on history alone, which is an unreliable indicator of true hypersensitivity.To promote and standardize reproducible skin testing with safe and nonirritant drug concentrations in the clinical practice, the European Network and European Academy of Allergy and Clinical Immunology (EAACI) Interest Group on Drug Allergy has performed a literature search on skin test drug concentration in MEDLINE and EMBASE, reviewed and evaluated the literature in five languages using the GRADE system for quality of evidence and strength of recommendation. Where the literature is poor, we have taken into consideration the collective experience of the group.We recommend drug concentration for skin testing aiming to achieve a specificity of at least 95%. It has been possible to recommend specific drug concentration for betalactam antibiotics, perioperative drugs, heparins, platinum salts and radiocontrast media. For many other drugs, there is insufficient evidence to recommend appropriate drug concentration. There is urgent need for multicentre studies designed to establish and validate drug skin test concentration using standard protocols. For most drugs, sensitivity of skin testing is higher in immediate hypersensitivity compared to nonimmediate hypersensitivity.
- Published
- 2014
16. Management of Patients with Patent Foramen Ovale and Cryptogenic Stroke: A Collaborative, Multidisciplinary, Position Paper: Executive Summary
- Author
-
Gualtiero Palareti, Serena Rakar, Gianluca Rigatelli, Christian Pristipino, Andrea Donti, Eustaquio Onorato, Gian Paolo Anzola, Antonio L. Bartorelli, Roberto Violini, Giuseppe Neri, Achille Gaspardone, Gian Paolo Ussia, Luigi Ballerini, Massimo Chessa, Moreno Cecconi, Gennaro Santoro, and Danilo Toni
- Subjects
Diagnostic Imaging ,medicine.medical_specialty ,Pediatrics ,Consensus ,patent foramen ovale ,Alternative medicine ,Cardiology ,Foramen Ovale, Patent ,Multidisciplinary approach ,Predictive Value of Tests ,Terminology as Topic ,embolic stroke ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Closure (psychology) ,Cooperative Behavior ,Foramen ovale (heart) ,Patient Care Team ,Executive summary ,treatment ,business.industry ,General Medicine ,medicine.disease ,Stroke ,medicine.anatomical_structure ,Treatment Outcome ,Italy ,Neurology ,Ischemic Attack, Transient ,Patent foramen ovale ,Position paper ,Interdisciplinary Communication ,Medical emergency ,Cardiology and Cardiovascular Medicine ,business ,Working group - Abstract
Objectives: To organize a common approach on the management of patent foramen ovale (PFO) and cryptogenic stroke that may be shared by different specialists. Background: The management of PFO related to cryptogenic stroke is controversial, despite an increase in interventional closure procedures. Methods: A consensus statement was developed by approaching Italian national cardiological, neurological, and hematological scientific societies. Task force members were identified by the president and/or the boards of each relevant scientific society or working group, as appropriate. Drafts were outlined by specific task force working groups. To obtain a widespread consensus, these drafts were merged and distributed to the scientific societies for local evaluation and revision by as many experts as possible. The ensuing final draft, merging all the revisions, was reviewed by the task force and finally approved by scientific societies. Results: Definitions of transient ischemic attack and both symptomatic and asymptomatic cryptogenic strokes were specified. A diagnostic workout was identified for patients with candidate event(s) and patient foramen ovale to define the probable pathogenesis of clinical events and to describe individual PFO characteristics. Further recommendations were provided regarding medical and interventional therapy considering individual risk factors of recurrence. Finally, follow-up evaluation was appraised. Conclusions: Available data provided the basis for a shared approach to management of cryptogenic ischemic cerebral events and PFO among different Italian scientific societies. Wider international initiatives on the topic are awaited. © 2013 Wiley Periodicals, Inc.
- Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.